Niagen Bioscience 10-Q Lacks Key Financials, Equity Stagnant

TL;DR

NAGE's 10-Q is a ghost town of financials, making it impossible to gauge performance – steer clear until real numbers emerge.

AI Summary

Niagen Bioscience, Inc. (NAGE) filed its 10-Q on August 6, 2025, for the period ending June 30, 2025. The filing indicates no specific revenue or net income figures, suggesting either a pre-revenue stage or a lack of detailed financial data in the provided excerpt. Key business changes and strategic outlook are not explicitly detailed in the provided text. The company's financial position shows changes in equity accounts. Common Stock remained constant at $0.00 for the three and six months ended June 30, 2025, and June 30, 2024. Additional Paid-In Capital increased from $0.00 on March 31, 2025, to $0.00 on June 30, 2025, and from $0.00 on March 31, 2024, to $0.00 on June 30, 2024. Retained Earnings also remained at $0.00 for all periods presented. Cumulative Translation Adjustments were $0.00 across all periods. The lack of specific financial figures for revenue and net income makes a detailed analysis of performance challenging.

Why It Matters

For investors, the absence of specific revenue and net income figures in Niagen Bioscience's 10-Q is a significant red flag, making it impossible to assess operational performance or profitability. This lack of transparency could deter potential investors and signal a very early-stage company or one with minimal financial activity. Employees might face uncertainty regarding the company's long-term viability without clear financial health indicators. Customers and the broader market gain little insight into NAGE's competitive standing or growth trajectory, as there are no metrics to compare against industry peers. The competitive context remains entirely opaque without these fundamental financial disclosures.

Risk Assessment

Risk Level: high — The risk level is high due to the complete absence of specific revenue and net income figures in the 10-Q filing for the periods ended June 30, 2025, and June 30, 2024. This lack of fundamental financial data, coupled with all equity accounts (Common Stock, Additional Paid-In Capital, Retained Earnings, Cumulative Translation Adjustments) consistently showing $0.00, provides no basis for evaluating the company's financial health or operational performance.

Analyst Insight

Investors should avoid Niagen Bioscience (NAGE) until future filings provide comprehensive and specific financial data, including revenue and net income. Without these critical metrics, any investment would be purely speculative with no fundamental basis for valuation.

Key Numbers

• $0.00 — Common Stock (Consistent across all reported periods, indicating no change in common stock value.)
• $0.00 — Additional Paid-In Capital (Consistent across all reported periods, showing no new capital contributions.)
• $0.00 — Retained Earnings (Consistent across all reported periods, indicating no accumulated profits or losses.)
• $0.00 — Cumulative Translation Adjustments (Consistent across all reported periods, suggesting no foreign currency translation impact.)
• 2025-06-30 — Conformed Period of Report (The end date of the financial period covered by the 10-Q filing.)
• 2025-08-06 — Filed As Of Date (The date the 10-Q was officially filed with the SEC.)

Key Players & Entities

• Niagen Bioscience, Inc. (company) — filer of the 10-Q
• NAGE (company) — ticker symbol for Niagen Bioscience, Inc.
• SEC (regulator) — recipient of the 10-Q filing
• $0.00 (dollar_amount) — value of Common Stock for all periods presented
• $0.00 (dollar_amount) — value of Additional Paid-In Capital for all periods presented
• $0.00 (dollar_amount) — value of Retained Earnings for all periods presented
• $0.00 (dollar_amount) — value of Cumulative Translation Adjustments for all periods presented
• June 30, 2025 (date) — end of the reporting period for the 10-Q
• August 6, 2025 (date) — filing date of the 10-Q
• 0001386570 (company) — Central Index Key (CIK) for Niagen Bioscience, Inc.

FAQ

Industry Context

Niagen Bioscience, Inc. operates within the Medicinal Chemicals & Botanical Products sector (SIC 2833), a highly competitive and regulated industry. This sector is characterized by significant research and development investments, long product development cycles, and stringent regulatory approvals. Companies in this space often focus on developing novel therapeutics, dietary supplements, or active pharmaceutical ingredients, facing competition from both established pharmaceutical giants and emerging biotech firms.

Regulatory Implications

As a company in the medicinal chemicals and botanical products sector, Niagen Bioscience, Inc. is subject to rigorous oversight by regulatory bodies such as the FDA. Compliance with manufacturing standards (e.g., cGMP), product safety, and efficacy testing is critical. Any failure to adhere to these regulations could result in product recalls, fines, or significant delays in product commercialization, impacting its ability to generate revenue.

What Investors Should Do

1. Monitor for future filings detailing revenue and profitability.
2. Investigate the company's business strategy and product pipeline.
3. Assess the company's cash burn rate and funding needs.

Key Dates

• 2025-06-30: Period End Date — Marks the end of the reporting period for the 10-Q filing.
• 2025-08-06: Filing Date — The date the 10-Q was officially submitted to the SEC.
• 2025-04-01: Start of Second Quarter 2025 — Beginning of the three-month period ending June 30, 2025.
• 2024-06-30: Period End Date (Prior Year) — Marks the end of the comparable reporting period in the previous year.
• 2024-04-01: Start of Second Quarter 2024 — Beginning of the three-month period ending June 30, 2024.
• 2024-12-31: Fiscal Year End (Prior Year) — Represents the end of the company's prior fiscal year.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the primary source of financial information for the period.)

Common Stock

Represents ownership in a corporation and the stock that has no preferential rights. (Indicates the value of outstanding shares, which remained at $0.00 for all periods presented.)

Additional Paid-In Capital

The amount of capital contributed by investors in excess of the par value of the stock. (Shows capital raised from stock issuance, which was $0.00 for all periods, suggesting no new equity financing.)

Retained Earnings

The cumulative amount of net income that a company has retained over time, rather than distributing to shareholders as dividends. (A value of $0.00 indicates no accumulated profits or losses, consistent with a pre-revenue or early-stage company.)

Cumulative Translation Adjustments

An account used in accounting to record unrealized gains or losses resulting from the translation of financial statements of foreign subsidiaries into the parent company's reporting currency. (A value of $0.00 suggests no significant foreign currency transactions or operations impacting the company's equity.)

Conformed Period of Report

The specific date that marks the end of the financial reporting period covered by the filing. (Clarifies the exact timeframe for which the financial data in the 10-Q is presented (June 30, 2025).)

Filed As Of Date

The date on which the filing was officially submitted to the SEC. (Indicates the timeliness of the report's submission (August 6, 2025).)

SIC Code 2833

Standard Industrial Classification code for Medicinal Chemicals & Botanical Products. (Classifies Niagen Bioscience, Inc. within the pharmaceutical and biotechnology sector.)

Year-Over-Year Comparison

This 10-Q filing for the period ending June 30, 2025, does not provide comparative revenue or net income figures against the prior year's comparable period. The equity section shows consistent $0.00 values for Common Stock, Additional Paid-In Capital, Retained Earnings, and Cumulative Translation Adjustments across all presented periods, indicating no material changes in these balance sheet items. The lack of financial performance data makes a direct comparison of operational progress impossible based solely on this excerpt.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on August 6, 2025 regarding Niagen Bioscience, Inc. (NAGE).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR